MAPT and Alzheimer disease: Data collected in humans show increased activation of GSK-3β in early-stage AD [24], while a consistent inhibition was observed in late-stage AD [25,26], thus suggesting that GSK-3β-mediated tau phosphorylation is among the earliest events during the progression of the pathology.